Integrareported 2Q20 orthopedic revenue of USD $11.2 million, -48.7% vs. 2Q19. The company endured -80% orthopedic revenue reductions in April. The quarter brought sequential improvements, with orthopedics recovering to mid-single-digit declines in June. Integra’s shoulder products showed the most growth and benefited from previously deferred procedures. The company expects 3Q revenue declines between -5% and -15% compared to the prior year, while 4Q revenues could approach 2019 levels.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Joint Replacement Extremities
$4.1
$9.1
($5.0)
(54.8%)
Trauma
$7.0
$12.6
($5.6)
(44.3%)
Total
$11.2
$21.8
($10.6)
(48.7%)
1H20
1H19
$ Chg
% Chg
Joint Replacement Extremities
$12.5
$18.2
($5.7)
(31.3%)
Trauma
$20.1
$26.2
($6.1)
(23.3%)
Total
$32.6
$44.4
($11.8)
(26.6%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
US
$7.8
$15.5
($7.7)
(49.4%)
OUS
$3.3
$6.3
($2.9)
(47%)
EMEA
$1.4
$2.9
($1.5)
(52.1%)
Asia Pacific
$1.4
$2.1
($0.7)
(31.2%)
Rest of World
$0.5
$1.3
($0.8)
(61.6%)
Total
$11.2
$21.8
($10.6)
(48.7%)
1H20
1H19
$ Chg
% Chg
US
$22.8
$31.7
($8.9)
(28.1%)
OUS
$9.8
$12.7
($2.9)
(22.9%)
EMEA
$4.2
$6.0
($1.8)
(30.1%)
Asia Pacific
$3.9
$4.4
($0.5)
(11.1%)
Rest of World
$1.8
$2.4
($0.6)
(26.4%)
Total
$32.6
$44.4
($11.8)
(26.6%)
Earnings
Amt
% of Sales
Sales
$258.7
Cost of Sales
$105.5
40.8%
Selling and Admin
$116.1
44.9%
R & D
$14.9
5.8%
Other
$22.5
8.7%
Net Earnings
($0.4)
0.1%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Integrareported 2Q20 orthopedic revenue of USD $11.2 million, -48.7% vs. 2Q19. The company endured -80% orthopedic revenue reductions in April. The quarter brought sequential improvements, with orthopedics recovering to mid-single-digit declines in June. Integra's shoulder products showed the most growth and benefited from previously...
Integrareported 2Q20 orthopedic revenue of USD $11.2 million, -48.7% vs. 2Q19. The company endured -80% orthopedic revenue reductions in April. The quarter brought sequential improvements, with orthopedics recovering to mid-single-digit declines in June. Integra’s shoulder products showed the most growth and benefited from previously deferred procedures. The company expects 3Q revenue declines between -5% and -15% compared to the prior year, while 4Q revenues could approach 2019 levels.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Joint Replacement Extremities
$4.1
$9.1
($5.0)
(54.8%)
Trauma
$7.0
$12.6
($5.6)
(44.3%)
Total
$11.2
$21.8
($10.6)
(48.7%)
1H20
1H19
$ Chg
% Chg
Joint Replacement Extremities
$12.5
$18.2
($5.7)
(31.3%)
Trauma
$20.1
$26.2
($6.1)
(23.3%)
Total
$32.6
$44.4
($11.8)
(26.6%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
US
$7.8
$15.5
($7.7)
(49.4%)
OUS
$3.3
$6.3
($2.9)
(47%)
EMEA
$1.4
$2.9
($1.5)
(52.1%)
Asia Pacific
$1.4
$2.1
($0.7)
(31.2%)
Rest of World
$0.5
$1.3
($0.8)
(61.6%)
Total
$11.2
$21.8
($10.6)
(48.7%)
1H20
1H19
$ Chg
% Chg
US
$22.8
$31.7
($8.9)
(28.1%)
OUS
$9.8
$12.7
($2.9)
(22.9%)
EMEA
$4.2
$6.0
($1.8)
(30.1%)
Asia Pacific
$3.9
$4.4
($0.5)
(11.1%)
Rest of World
$1.8
$2.4
($0.6)
(26.4%)
Total
$32.6
$44.4
($11.8)
(26.6%)
Earnings
Amt
% of Sales
Sales
$258.7
Cost of Sales
$105.5
40.8%
Selling and Admin
$116.1
44.9%
R & D
$14.9
5.8%
Other
$22.5
8.7%
Net Earnings
($0.4)
0.1%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
